期刊文献+

房颤的抗凝治疗

下载PDF
导出
摘要 目的:研究房颤患者抗凝治疗的情况,探讨房颤患者抗凝治疗的意史。方法:随机选取2012年2月至2013年2月的80例房颤患者的治疗资料进行回顾性分析,观察房颤患者抗凝治疗的效果。结果:两组患者的抗凝治疗情况经观察比较,结果显示,心脏瓣膜病所致房颤患者的抗凝治疗率显著高于非瓣膜病性房颤患者,差异有统计学意义,P〈0.05;两组患者的抗凝迭标情况,结果显示,心脏瓣膜病性房颤患者抗凝达标率高于心脏非瓣膜病性房颤患者抗凝迭标率,差异显著,有统计学意义,P〈0.05。结论:房颤抗凝的效果与多种因素有关,只有人们意识到房颤抗凝的重要性才能减少积极预防,减少房颤的发生。
出处 《药物与人》 2015年第1期83-83,共1页 Medicine & People
  • 相关文献

参考文献4

二级参考文献38

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation : the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010,31:2369.
  • 3Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest, 2010,137:263.
  • 4Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ, 2010,342: d124.
  • 5Ogilvie IM, Newton N, Wetner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med, 2010, 123:658.
  • 6Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clo-pidogrel Trial with Irbesartan fbr prevention of Vascular Events ( AC- TIVE W) : a randomised controlled trial. Lancet, 2006,367:1903.
  • 7Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med, 2009,360: 2066.
  • 8ROCKET AF Study investigators. Rivaroxaban-Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J, 2010,159:340.
  • 9Eikelboom JW, O'Donnell M, Yusuf S, et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable foi" vitamin K antagonist treatment. Am Heart J, 2010,159:348.
  • 10Lopes RD, Alexander JH, M-Khatib SM, et al. Apixaban for reduction in stroke and other thromboemboLic events in atrial fibrillation (ARIS- TOTLE) trial: design and rationale. Am Heart J, 2010,159:331.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部